Loading company…
Sutro Biopharma develops cancer therapies, including site-specific antibody-drug conjugates and biologics.
Founded in 2003 and based in South San Francisco, Sutro Biopharma develops cancer therapeutics, including site-specific antibody-drug conjugates and other biologics. Its XpressCF® system is used to produce these drug candidates. The company works with pharmaceutical firms and research institutions through development collaborations and licensing agreements. Bill Newell is CEO; Sutro reported USD 62.04 mn in revenue in 2024.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in